Related Experiment Video
Updated: Jul 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
[Non-small-cell lung cancer]
Hirotoshi Akita1, Ichiro Kinoshita
1Dept. of Medical Oncology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.
Abstract:
Molecular targeted therapy in combination with chemotherapy or thoracic radiotherapy has been studied in clinical trials. Gefitinib or erlotinib in combination with standard chemotherapy did not improve efficacy on survival over standard chemotherapy alone in chemotherapy-naive patients with advanced NSCLC. On the other hand, bevacizumab in combination with standard chemotherapy improved survival in chemotherapy-naive patients with advanced NSCLC, excluding squamous cell carcinoma. Multi-target tyrosine kinase inhibitors in combination with standard chemotherapy, and anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in combination with thoracic radiotherapy, are under clinical trials.
